PharMerica Corporation (NYSE: PMC), a national provider of institutional pharmacy, specialty infusion and hospital pharmacy management services, today issued the following statement:
“As previously disclosed in the Corporation's 10-K and 10-Q Reports, PharMerica Corporation is responding to investigations by the U.S. Attorneys and by the Drug Enforcement Agency into allegations that the Corporation failed to comply with various laws and regulations relating to the control and dispensing of certain controlled substances as well as the potential filing of false claims for payments of certain controlled substances that the Corporation dispensed to nursing home residents. The Corporation has been fully cooperative with the investigations. As part of these investigations, on August 9, 2013, the U.S. Department of Justice, through the U.S. Attorney’s Office for the Eastern District of Wisconsin, filed a complaint in the United States District Court for the Eastern District of Wisconsin against the Corporation alleging that the Corporation violated the False Claims Act and the Controlled Substances Act by dispensing controlled drugs without valid prescriptions and causing claims for illegally dispensed drugs to be submitted to the Medicare program. The Corporation disputes the premises of this lawsuit and the related litigation and intends to vigorously defend itself against these allegations.”
PharMerica Corporation is a leading institutional pharmacy services company that services healthcare facilities in the United States, provides pharmacy management services to hospitals, and also provides specialty infusion services to patients outside a hospital setting. As of June 30, 2013, PharMerica operated 90 institutional pharmacies and 12 specialty infusion centers in 45 states. PharMerica’s customers are institutional healthcare providers, such as skilled nursing facilities, nursing centers, assisted living facilities, hospitals, individuals receiving in-home care and other long-term alternative care providers.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts